Shaw and Partners Chief Investment Officer Martin Crabbe outlines a four-part investment strategy, focusing on growth, financial conditions, central bank policy and valuation. He notes that valuations remain high. He advises investors to adopt an active strategy, selecting individual growth-oriented stocks instead of relying on index funds.
Copyright 2024 – Finance News Network
Source: Finance News Network
24 Nov 2020 - Altech Chemicals Limited (ASX:ATC) Managing Director Iggy Tan provides an update on construction of the company's high purity alumina (HPA) processing plant in Malaysia, its funding plans for the next phase of construction, growing HPA applications and plans for a second HPA plant in Saxony, Germany.
Read More24 Feb 2022 - Shaw and Partners Chief Investment Officer Martin Crabb discusses the sectors to invest in given slowing global growth, tightening financial conditions, the risk of inflation and geopolitical imbalances.
Read More11 Mar 2021 - Rural Funds Group Limited (ASX:RFF) General Manager - Investor Relations and Marketing, James Powell, presents on the group's HY21 results.
Read More09 Mar 2020 - Lithium Power International Limited (ASX:LPI) Managing Director and CEO Cristobal Garcia-Huidobro and Executive Director and CFO Andrew Phillips discuss the Environmental Approval for the company's Maricunga lithium brine project in Northern Chile, what this means for the project, and what’s planned.
Read More21 Oct 2024 - Ken Morrison, CEO of the Bradfield Development Authority, discusses building Australia's first new city in a century, a high-tech urban project linked to the new Western Sydney International Airport.
Read More09 Sep 2024 - ABx Group Limited (ASX:ABX) Managing Director and CEO Dr Mark Cooksey discusses the significance of the company's memorandum of understanding with Ucore Rare Metals.
Read More25 Mar 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt provides an update on the company's pipeline of clinical trials, focusing on results in head and neck cancer, lung cancer and breast cancer.
Read More25 Oct 2023 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses efficacy results for the company's glioblastoma therapy.
Read More09 Jun 2023 - Shaw and Partners Chief Investment Officer Martin Crabb discusses financial conditions, global growth and central bank decision-making.
Read More31 Oct 2023 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress of the company's drug candidates, highlighting promising data from the 2023 ESMO Congress.
Read More
